DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0260639 A1 Nakamura Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0260639 A1 Nakamura Et Al US 2005O260639A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0260639 A1 Nakamura et al. (43) Pub. Date: Nov. 24, 2005 (54) METHOD FOR DIAGNOSING PANCREATIC Related U.S. Application Data CANCER (63) Continuation-in-part of application No. PCT/JPO3/ 11817, filed on Sep. 17, 2003. (75) Inventors: Yusuke Nakamura, Yokohama-shi (JP); Toyomasa Katagiri, Shinagawa-ku (60) Provisional application No. 60/555,809, filed on Mar. 24, 2004. Provisional application No. 60/450,889, (JP); Hidewaki Nakagawa, filed on Feb. 28, 2003. Provisional application No. Shinagawa-ku (JP) 60/414,872, filed on Sep. 30, 2002. Publication Classification Correspondence Address: TOWNSEND AND TOWNSEND AND CREW, (51) Int. Cl. .................................................. C12O 1/68 LLP (52) U.S. Cl. .................................................................. 435/6 TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the (73) Assignees: Oncotherapy Science, Inc., Kawasaki diagnostic method involves determining the expression level shi (JP); The University of Tokyo, Bun of PNC-associated gene that discriminates between PNC kyo-ku (JP) cells and normal cells. The present invention further pro vides methods of Screening for therapeutic agents useful in (21) Appl. No.: 11/090,739 the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a Subject (22) Filed: Mar. 24, 2005 against pancreatic cancer. Patent Application Publication Nov. 24, 2005 Sheet 1 of 16 US 2005/0260639 A1 FG 1 Patent Application Publication Nov. 24, 2005 Sheet 2 of 16 US 2005/0260639 A1 s - to co on S 2 2 O C C C D C C C D C) () () O U O n. O. all all all a ?al all all a fall a Z TUBA 12 : APP 1012 13 : ARHGDB 1212 15: ATDC 1012 16 : ATP1B3 1212 19: BIRC5 1212 22 : BUB1B 12/12 33: CELSR3 9/12 35: CKS1 7112 36 : CKS2 11112 48 : CYP2S1 8/12 54: E2-EPF to six tax xxx 8/12 56 : ELF4 11/12 57 : ENC1 7112 59 : EPHA4 9/12 61 : Evi-1 11/12 63 : FOXM1 11112 73 : GW112 7112 74 : GYS1 10/12 77 : HDGF 10/12 Patent Application Publication Nov. 24, 2005 Sheet 3 of 16 US 2005/0260639 A1 FIG.2-2 s vs N O OC O. V.cN V(Y) VNr. vanLO vsto N- vOO E () () () (d O C C C D cd O c) O O a - A - all all all all all all d. a 2 TUBA 83 : HOXB7 84 : h AD 612 -colony10 12/12 102: KNSL6 10/12 103: KPNB2 10/12 11.5: MMP11 11/12 120: MYBL2 10/12 125: OAS1 t sis an ess 8/12 127: ORP150 fi ass 3% O 412 132: PCON3 141: PPM1B was a w tw. At 3:...at 31 12 12/12 143: PRC1 6/12 149: PSCA , , , , was e ... 9/12 152: PYCR1 O O 155: RBMS1 12/12 157: REGIV as as O - ". 164: S100P 169: SFN 170: SLC12A2 5/12 173: SLC2A1 Patent Application Publication Nov. 24, 2005 Sheet 4 of 16 US 2005/0260639 A1 FG.2-3 - so to a S 2 2 2 CD C C C C C C C D C C D C ( ) O - C - O - O - all a a a Z TUBA 178: SRD5A1 8/12 180: TCEA1 8/12 184: TK1 10/12 188: UBCH10 10/12 196: WHSC1 8/12 198: FLJ10134 8/12 2O3: 5/12 208: KAAO101 12/12 217: KIAA1624 9/12 218: KIAA1808 8/12 225: FLU21504 11112 231: WANGL1 6/12 234: EST 11/12 239: EST 8/12 245: EST - - - - - - 6/12 253: EST 12/12 254: FXYD3 9/12 259: EST u au it 6/12 Patent Application Publication Nov. 24, 2005 Sheet 6 of 16 US 2005/0260639 A1 FG4 Liver Liver meta meta () (+) ANPEP DKFZP586OO223 MMP12 PTMS MYG1 3 ES PASSA MAN1B1 PKM2 EDH2KIAAO668 ZNF282 BZRP . FGG PLOD ; FBL KRT8AS28 EST RP4-751H13 ... YKT6 FLJ13102 EST SDCCAG8 HEXA EMK1 GPRK7 HSPC138 PPP1 CC WAS Patent Application Publication Nov. 24, 2005 Sheet 7 of 16 US 2005/0260639 A1 FIG.5 (A-1) NR4A1 KIAAO469 KIAAO903 GRB10 GP is MTMR1 CSH2 DKFZP761C169 TIMM9 CTSB HSPC164 GOLGA3 BRE SAHBP1 TPD52L2 HSPD1 HSPA1A AARS YME1L1 RALY EST WARS SENP2 MRPL3 MLLT4 CCT6A ARPC3 HSP 105B SHMT2 RPL37A POH1 EST GLS FLJ10803 ... EST - NPD002 GRB14 Patent Application Publication Nov. 24, 2005 Sheet 8 of 16 US 2005/0260639 A1 FIG.5 (A-2) LCAT RAGE ARGBP2 T. E. ATP1A1EST SCAP EIF3S8. SYNGR2 GPRC5C is EST EST BZRP PRSS1 TUFM E. E. OARSSERPNA4 it. GSTM1 CBARA1 HK1 FLOT2 RPS11 LOC51 189 DAG1 PRKACB AGR2 RPL38 TPM3 PSMB4 ATP5O PPP3CA PM5 MAC30 ACO1 DBY EST RPL17 EEF1G RPS2 RPLP1 RPL23A RPL13A CATX-8 CASP4 RPLP2 Patent Application Publication Nov. 24, 2005 Sheet 9 of 16 US 2005/0260639 A1 FIG.5 (B) 4.6 2 30 60 90 Number of discriminating genes (C) -100 Number of discriminating genes o early-recurrent cases 0 late-recurrent cases Patent Application Publication Nov. 24, 2005 Sheet 10 of 16 US 2005/0260639 A1 FG.6 (A) 90d O80d º?Od (B) d.©||9 O9Od O8Od O6Od O9||Od O94,Od Patent Application Publication Nov. 24, 2005 Sheet 11 of 16 US 2005/0260639 A1 FG.7 CDH3 normal pancreatic du Patent Application Publication Nov. 24, 2005 Sheet 12 of 16 US 2005/0260639 A1 FG. 8-1 (A) PCIDH1 Patent Application Publication Nov. 24, 2005 Sheet 13 of 16 US 2005/0260639 A1 FIG.8-2 (C) GPR107 | Patent Application Publication Nov. 24, 2005 Sheet 14 of 16 US 2005/0260639 A1 FIG.9 (A) PCDH1 ACTB (B) PK-45P 41 Os EGFPsi (C) O.6 0.5 0.4 0.3 0.2 0.1 41 Osi EGFP Si Patent Application Publication Nov. 24, 2005 Sheet 15 of 16 US 2005/0260639 A1 FIG.10 Patent Application Publication Nov. 24, 2005 Sheet 16 of 16 US 2005/0260639 A1 FG.11 (B)KLM-1 1003si EGFPsi (C) 10O3Si EGFPSi US 2005/0260639 A1 Nov. 24, 2005 METHOD FOR DIAGNOSING PANCREATIC fusion proteins, has been developed to treat chronic myel CANCER ogenous leukemias wherein constitutive activation of bcr abl tyrosine kinase plays a crucial role in the transformation PRIORITY INFORMATION of leukocytes. Agents of these kinds are designed to Suppress 0001. This application is a continuation-in-part of PCT/ oncogenic activity of specific gene products (Fujita et al., JP2003/011817 (WO 2004/031412), which claims priority Cancer Res 61.7722-6 (2001)). Therefore, gene products to U.S. Provisional Applications Ser. No. 60/414,872, filed commonly up-regulated in cancerous cells may serve as Sep. 30, 2002 and Ser. No. 60/450,889, filed Feb. 28, 2003. potential targets for developing novel anti-cancer agents. This application also claims the benefit of Ser. No. 60/555, 0006. It has been demonstrated that CD8+ cytotoxic T 809 filed Mar. 24, 2004. All of these applications are lymphocytes (CTLs) recognize epitope peptides derived incorporated herein by reference. from tumor-associated antigens (TAAS) presented on MHC Class I molecule, and lyse tumor cells. Since the discovery TECHNICAL FIELD of MAGE family as the first example of TAAS, many other TAAS have been discovered using immunological 0002 The invention relates to methods of diagnosing approaches (Boon, Int J Cancer 54: 177-80 (1993); Boon pancreatic cancer. and van der Bruggen, J Exp Med 183: 725-9 (1996); van der Bruggen et al., Science 254: 1643-7 (1991); Brichard et al., BACKGROUND OF THE INVENTION J Exp Med 178: 489-95 (1993); Kawakami et al., J Exp Med 0.003 Pancreatic cancer has one of the highest mortality 180: 347-52 (1994)). Some of the discovered TAAS are now rates of any malignancy, and the 5-year-Survival rate of in the Stage of clinical development as targets of immuno patients is 4%. 28000 patients with pancreatic cancer are therapy. TAAS discovered so far include MAGE (van der diagnosed each year, and nearly all patients will die of their Bruggen et al., Science 254: 1643-7 (1991)), gp100 disease (1). The poor prognosis of this malignancy is a result (Kawakami et al., J Exp Med 180: 347-52 (1994)), SART of the difficulty of early diagnosis and poor response to (Shichijo et al., J Exp Med 187: 277-88 (1998)), and current therapeutic methods (1, 2). In particular currently no NY-ESO-1 (Chen et al., Proc Natl Acad Sci USA94: 1914-8 tumor markers are identified that allow reliable Screening at (1997)). On the other hand, gene products which had been an early, potentially curative Stage of the disease. demonstrated to be specifically over-expressed in tumor 0004 cDNA microarray technologies have enabled to cells, have been shown to be recognized as targets inducing obtain comprehensive profiles of gene expression in normal cellular immune responses. Such gene products include p53 and malignant cells, and compare the gene expression in (Umano et al., Brit J Cancer 84: 1052-7 (2001)), HER2/neu malignant and corresponding normal cells (Okabe et al., (Tanaka et al., Brit J Cancer 84: 94-9 (2001)), CEA (Nukaya Cancer Res 61:2129-37 (2001); Kitahara et al., Cancer Res et al., Int J Cancer 80: 92-7 (1999)), and so on. 61: 3544-9 (2001); Lin et al., Oncogene 21:4120-8 (2002); 0007. In spite of significant progress in basic and clinical Hasegawa et al., Cancer Res 62:7012-7 (2002)). This research concerning TAAS (Rosenbeg et al., Nature Med 4: approach enables to disclose the complex nature of cancer 321-7 (1998); Mukherji et al., Proc Natl Acad Sci USA 92: cells, and helps to understand the mechanism of carcino 8078-82 (1995); Hu et al., Cancer Res 56: 2479-83 (1996)), genesis.
Load more

Recommended publications
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2
    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
    [Show full text]
  • Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
    ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Local Genetic and Environmental Factors in Asthma Disease Pathogenesis: Chronicity and Persistence Mechanisms
    Eur Respir J 2007; 29: 793–803 DOI: 10.1183/09031936.00087506 CopyrightßERS Journals Ltd 2007 SERIES ‘‘GENETICS OF ASTHMA AND COPD IN THE POSTGENOME ERA’’ Edited by E. von Mutius, M. Kabesch and F. Kauffmann Number 4 in this Series Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms S.T. Holgate*, D.E. Davies*, R.M. Powell*, P.H. Howarth*, H.M. Haitchi# and J.W. Holloway" ABSTRACT: While asthma is an inflammatory disorder of the airways usually associated with AFFILIATIONS atopy, an important additional component is involvement of the epithelium and underlying *Allergy and Inflammation Research, Division of Infection, Inflammation mesenchyme acting as a trophic unit (EMTU). and Repair, In addition to allergens, a wide range of environmental factors interact with the EMTU, such as #IIR Division and virus infections, environmental tobacco smoke and pollutants, to initiate tissue damage and "Division of Human Genetics, School aberrant repair responses that are translated into remodelling of the airways. While candidate of Medicine, Southampton General Hospital, Southampton, UK. gene association studies have revealed polymorphic variants that influence asthmatic inflamma- tion, positional cloning of previously unknown genes is identifying a high proportion of novel CORRESPONDENCE genes in the EMTU. S.T. Holgate Dipeptidyl peptidase (DPP) 10 and disintegrin and metalloproteinase (ADAM)33 are newly Allergy and Inflammation Research MP810 identified genes strongly associated with asthma that are preferentially expressed in the airway Level D epithelium and underlying mesenchyme, respectively. Centre Block Also of increasing importance is the recognition that genes associated with asthma and atopy Southampton General Hospital have important interactions with the environment through epigenetic mechanisms that influence Southampton SO16 6YD UK their expression.
    [Show full text]
  • PCDH1 Antibody (Monoclonal) (M01) Mouse Monoclonal Antibody Raised Against a Partial Recombinant PCDH1
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PCDH1 Antibody (monoclonal) (M01) Mouse monoclonal antibody raised against a partial recombinant PCDH1. Catalog # AT3210a Specification PCDH1 Antibody (monoclonal) (M01) - Product Information Application IF, WB, IHC, E Primary Accession Q08174 Other Accession NM_002587 Reactivity Human Host mouse Clonality Monoclonal Isotype IgG1 Kappa Calculated MW 114743 PCDH1 Antibody (monoclonal) (M01) - Additional Information Immunofluorescence of monoclonal antibody to PCDH1 on A-431 cell. [antibody concentration 10 ug/ml] Gene ID 5097 Other Names Protocadherin-1, Cadherin-like protein 1, Protocadherin-42, PC42, PCDH1 Target/Specificity PCDH1 (NP_002578, 62 a.a. ~ 169 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution WB~~1:500~1000 Format Clear, colorless solution in phosphate Antibody Reactive Against Recombinant buffered saline, pH 7.2 . Protein.Western Blot detection against Immunogen (37.62 KDa) . Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Precautions PCDH1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. PCDH1 Antibody (monoclonal) (M01) - Protocols Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety • Cell Culture PCDH1 monoclonal antibody (M01), clone 5D5 Western Blot analysis of PCDH1 expression in A-431 ( (Cat # AT3210a ) Immunoperoxidase of monoclonal antibody to PCDH1 on formalin-fixed paraffin-embedded human salivary gland.
    [Show full text]
  • Global Alterations to the Choroid Plexus Blood-CSF Barrier in Amyotrophic Lateral Sclerosis J
    Saul et al. Acta Neuropathologica Communications (2020) 8:92 https://doi.org/10.1186/s40478-020-00968-9 RESEARCH Open Access Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis J. Saul1,2, E. Hutchins3, R. Reiman3, M. Saul4, L. W. Ostrow5, B. T. Harris6, K. Van Keuren-Jensen3, R. Bowser1,2 and N. Bakkar1,2* Abstract The choroid plexus (CP) is a highly vascularized structure located in the ventricles that forms the blood-CSF barrier (BCSFB) and separates the blood from the cerebrospinal fluid (CSF). In addition to its role as a physical barrier, the CP functions in CSF secretion, transport of nutrients into the central nervous system (CNS) and a gated point of entry of circulating immune cells into the CNS. Aging and neurodegeneration have been reported to affect CP morphology and function and increase protein leakage from blood to the CSF. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease associated with both upper and lower motor neuron loss, as well as altered proteomic and metabolomic signatures in the CSF. The role of the BCSFB and the CP in ALS is unknown. Here we describe a transcriptomic and ultrastructural analysis of BCSFB and CP alterations in human postmortem tissues from ALS and non-neurologic disease controls. ALS-CP exhibited widespread disruptions in tight junctional components of the CP epithelial layer and vascular integrity. In addition, we detected loss of pericytes around ALS blood vessels, accompanied by activation of platelet aggregation markers vWF and Fibrinogen, reminiscent of vascular injury. To investigate the immune component of ALS-CP, we conducted a comprehensive analysis of cytokines and chemokine panels in CP lysates and found a significant down-regulation of M- CSF and V-CAM1 in ALS, as well as up-regulation of VEGF-A protein.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Placental Transcriptome Adaptations to Maternal Nutrient Restriction in Sheep
    International Journal of Molecular Sciences Article Placental Transcriptome Adaptations to Maternal Nutrient Restriction in Sheep Chelsie B. Steinhauser 1,†, Colleen A. Lambo 2,†, Katharine Askelson 1, Gregory W. Burns 3, Susanta K. Behura 4,5, Thomas E. Spencer 4, Fuller W. Bazer 1 and Michael Carey Satterfield 1,* 1 Department of Animal Science, Texas A & M University, College Station, TX 77843, USA; [email protected] (C.B.S.); [email protected] (K.A.); [email protected] (F.W.B.) 2 Department of Veterinary Physiology and Pharmacology, Texas A & M University, College Station, TX 77843, USA; [email protected] 3 Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, Grand Rapids, MI 49503, USA; [email protected] 4 Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA; [email protected] (S.K.B.); [email protected] (T.E.S.) 5 Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65211, USA * Correspondence: csatterfi[email protected]; Tel.: +1-979-845-6448 † These authors contributed equally to this work. Abstract: Placental development is modified in response to maternal nutrient restriction (NR), resulting in a spectrum of fetal growth rates. Pregnant sheep carrying singleton fetuses and fed either 100% (n = 8) or 50% (NR; n = 28) of their National Research Council (NRC) recommended intake from days 35–135 of pregnancy were used to elucidate placentome transcriptome alterations at both Citation: Steinhauser, C.B.; Lambo, day 70 and day 135. NR fetuses were further designated into upper (NR NonSGA; n = 7) and lower C.A.; Askelson, K.; Burns, G.W.; quartiles (NR SGA; n = 7) based on day 135 fetal weight.
    [Show full text]
  • Cell Adhesion Molecules in Normal Skin and Melanoma
    biomolecules Review Cell Adhesion Molecules in Normal Skin and Melanoma Cian D’Arcy and Christina Kiel * Systems Biology Ireland & UCD Charles Institute of Dermatology, School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +353-1-716-6344 Abstract: Cell adhesion molecules (CAMs) of the cadherin, integrin, immunoglobulin, and selectin protein families are indispensable for the formation and maintenance of multicellular tissues, espe- cially epithelia. In the epidermis, they are involved in cell–cell contacts and in cellular interactions with the extracellular matrix (ECM), thereby contributing to the structural integrity and barrier for- mation of the skin. Bulk and single cell RNA sequencing data show that >170 CAMs are expressed in the healthy human skin, with high expression levels in melanocytes, keratinocytes, endothelial, and smooth muscle cells. Alterations in expression levels of CAMs are involved in melanoma propagation, interaction with the microenvironment, and metastasis. Recent mechanistic analyses together with protein and gene expression data provide a better picture of the role of CAMs in the context of skin physiology and melanoma. Here, we review progress in the field and discuss molecular mechanisms in light of gene expression profiles, including recent single cell RNA expression information. We highlight key adhesion molecules in melanoma, which can guide the identification of pathways and Citation: D’Arcy, C.; Kiel, C. Cell strategies for novel anti-melanoma therapies. Adhesion Molecules in Normal Skin and Melanoma. Biomolecules 2021, 11, Keywords: cadherins; GTEx consortium; Human Protein Atlas; integrins; melanocytes; single cell 1213. https://doi.org/10.3390/ RNA sequencing; selectins; tumour microenvironment biom11081213 Academic Editor: Sang-Han Lee 1.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]